{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:21:39Z","timestamp":1786990899956,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Rajiv Gandhi National Fellowship","award":["RGNF-2014-15-ST-GUJ-57277"],"award-info":[{"award-number":["RGNF-2014-15-ST-GUJ-57277"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ijtb.2018.07.004","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T12:52:47Z","timestamp":1531313567000},"page":"12-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Development of new drug-regimens against multidrug-resistant tuberculosis"],"prefix":"10.1016","volume":"66","author":[{"given":"Mahesh S.","family":"Vasava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha G.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay K.","family":"Rathwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2018.07.004_bib1","series-title":"WHO Global Reports 2015","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.ijtb.2018.07.004_bib2","series-title":"TB India Annual Reports.2016 RNTCP","author":"Central TB division","year":"2016"},{"key":"10.1016\/j.ijtb.2018.07.004_bib3","series-title":"Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.ijtb.2018.07.004_bib4","unstructured":"http:\/\/www.tbfacts.org\/drug-resistant-tb-in-india\/#sthash.IrCYIdER.dpuf. Accessed 21 November 2016."},{"key":"10.1016\/j.ijtb.2018.07.004_bib5","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1128\/AAC.01197-08","article-title":"Molecular genetics of para aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis","volume":"53","author":"Mathys","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2018.07.004_bib6","unstructured":"World Health Organization. http:\/\/www.who.int\/features\/qa\/79\/en\/. Accessed 22 December 2016."},{"key":"10.1016\/j.ijtb.2018.07.004_bib7","first-page":"354","article-title":"Extrapulmonary tuberculosis","volume":"120","author":"Sharma","year":"2004","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ijtb.2018.07.004_bib8","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMra1200894","article-title":"Tuberculosis","volume":"368","author":"Zumla","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijtb.2018.07.004_bib9","first-page":"1176","article-title":"Notice to readers: revised definition of extensively drug-resistant tuberculosis","volume":"55","author":"CDC","year":"2006","journal-title":"MMWR"},{"issue":"1","key":"10.1016\/j.ijtb.2018.07.004_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1054\/tuld.1998.0002","article-title":"Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update","volume":"79","author":"Ramaswamy","year":"1998","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.ijtb.2018.07.004_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tube.2010.09.008","article-title":"TubercuList\u201310 years after","volume":"91","author":"Lew","year":"2011","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijtb.2018.07.004_bib12","first-page":"238","article-title":"Directly observed treatment, short-course strategy and multidrugresistant tuberculosis: are any modifications required?","volume":"78","author":"Bastian","year":"2000","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ijtb.2018.07.004_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0962-8479(94)90096-5","article-title":"Drug-resistant tuberculosis :laboratory issues. World Health Organization recommendations","volume":"75","author":"Vareldzis","year":"1994","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.ijtb.2018.07.004_bib14","series-title":"Crofton and Douglas's Respiratory Diseases","first-page":"5.278","article-title":"Tuberculosis","author":"Citron","year":"1987"},{"key":"10.1016\/j.ijtb.2018.07.004_bib15","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1086\/339818","article-title":"Worldwide incidence of multidrug-resistant tuberculosis","volume":"185","author":"Dye","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijtb.2018.07.004_bib16","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1128\/AAC.06125-11","article-title":"Phase II dose-ranging trial of the early bactericidal activity of PA-824","volume":"56","author":"Diacon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2018.07.004_bib17","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.4155\/fmc.11.90","article-title":"Nitroimidazoles for the treatment of TB: past, present and future","volume":"3","author":"Mukherjee","year":"2011","journal-title":"Future Med Chem"},{"issue":"6789","key":"10.1016\/j.ijtb.2018.07.004_bib18","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"issue":"9846","key":"10.1016\/j.ijtb.2018.07.004_bib19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(12)61080-0","article-title":"14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial","volume":"380","author":"Diacon","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ijtb.2018.07.004_bib20","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40265-014-0241-5","article-title":"Delamanid: first global approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ijtb.2018.07.004_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tubercu-losis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ijtb.2018.07.004_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nchembio884","article-title":"Diarylquinolines target subunit c of mycobacterial ATP synthase","volume":"3","author":"Koul","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.ijtb.2018.07.004_bib23","unstructured":"European Medicines Agency. CHMP Assessment Report: SIRTURO. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_Initial_authorisation\/human\/002614\/WC500158728.pdf. Accessed 25 December 2016."},{"issue":"5707","key":"10.1016\/j.ijtb.2018.07.004_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ijtb.2018.07.004_bib25","first-page":"724","article-title":"Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis","author":"Pym","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2018.07.004_bib26","unstructured":"International Union against Tuberculosis and Lung Disease. Current Trials: STREAM clinical trial to test first all-oral MDR-TB treatment regimen. www.theunion.org\/what-we-do\/research\/clinical-trials. Accessed 27 December 2016."},{"key":"10.1016\/j.ijtb.2018.07.004_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/1745-6215-15-353","article-title":"Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial","volume":"15","author":"Nunn","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.ijtb.2018.07.004_bib28","unstructured":"http:\/\/www.outsourcing-pharma.com\/Preclinical-Research\/Macrolide-drug-class-extended-to-treat-TB. Accessed 9 January 2017."},{"key":"10.1016\/j.ijtb.2018.07.004_bib29","unstructured":"http:\/\/www.newtbdrugs.org\/pipeline\/discovery. Accessed 9 January 2017."},{"key":"10.1016\/j.ijtb.2018.07.004_bib30","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S1472-9792(08)70036-2","article-title":"Structure-activity relationships of macrolides against Mycobacterium tuberculosis","volume":"88","author":"Zhu","year":"2008","journal-title":"Tuberculosis"},{"issue":"4","key":"10.1016\/j.ijtb.2018.07.004_bib31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.ijtb.2018.07.004_bib32","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ijtb.2018.07.004_bib33","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1021\/jacs.5b13008","article-title":"Ribosome-templated azide\u2013alkyne cycloadditions: synthesis of potent macrolide antibiotics by in situ click Chemistry","volume":"138","author":"Glassford","year":"2016","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ijtb.2018.07.004_bib34","series-title":"Guidelines for the Programmatic Management of Drug-resistant Tuberculosis","author":"World Health Organization","year":"2011"},{"key":"10.1016\/j.ijtb.2018.07.004_bib35","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0163-4453(09)60009-8","article-title":"Linezolid: a review of safety and tolerability","volume":"59","author":"Vinh","year":"2009","journal-title":"J Infect"},{"key":"10.1016\/j.ijtb.2018.07.004_bib36","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1021\/jm800379d","article-title":"Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ri-bosomal subunit","volume":"51","author":"Ippolito","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijtb.2018.07.004_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1749-6632.2011.05962.x","article-title":"Linezolid, the first oxazolidinone an-tibacterial agent","volume":"1222","author":"Leach","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijtb.2018.07.004_bib38","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0732-8893(91)90002-W","article-title":"Oxazolidinones, a new class of synthetic antituberculosis agent: in\u00a0vitro and in\u00a0vivo activities of DuP-721 against Mycobacterium tuberculosis","volume":"14","author":"Ashtekar","year":"1991","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.ijtb.2018.07.004_bib39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1183\/09031936.00009509","article-title":"A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis","volume":"34","author":"Migliori","year":"2009","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ijtb.2018.07.004_bib40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.2011.06330.x","article-title":"The oxazolidinones: past, present, and future","volume":"1241","author":"Shaw","year":"2011","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.ijtb.2018.07.004_bib41","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1128\/AAC.01903-13","article-title":"Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis","volume":"58","author":"Balasubramanian","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2018.07.004_bib42","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/AAC.00076-10","article-title":"Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections","volume":"5","author":"Prokocimer","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2018.07.004_bib43","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1128\/AAC.00228-09","article-title":"In\u00a0vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent","volume":"53","author":"Schaadt","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.ijtb.2018.07.004_bib44","doi-asserted-by":"crossref","first-page":"68917","DOI":"10.1371\/journal.pone.0068917","article-title":"In\u00a0vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori","volume":"8","author":"Makobongo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijtb.2018.07.004_bib45","series-title":"45th IDSA; Annual: Meeting, 2007 Oct 4\u20137; San Diego, CA, USA","article-title":"Phase 1 safety and pharmacokinetics of SQ109, a new diamine antituberculosis drug","author":"Horwith","year":"2007"},{"issue":"5","key":"10.1016\/j.ijtb.2018.07.004_bib46","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/jac\/dki319","article-title":"Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines","volume":"56","author":"Protopopova","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.ijtb.2018.07.004_bib47","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1128\/AAC.48.12.4550-4555.2004","article-title":"Rapid, simple in\u00a0vivo screen for new drugs active against Mycobacterium tuberculosis","volume":"48","author":"Nikonenko","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2018.07.004_bib48","series-title":"Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination","author":"US Department of Health and Human Services","year":"2010"},{"key":"10.1016\/j.ijtb.2018.07.004_bib49","first-page":"2409","article-title":"Preparation of new pyridinic thioamides active in experimental tuberculosis","volume":"242","author":"Libermann","year":"1956","journal-title":"CR Hebd Seances Acad Sci"},{"issue":"10","key":"10.1016\/j.ijtb.2018.07.004_bib50","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nri1704","article-title":"Tuberculosis control in the era of HIV","volume":"5","author":"Nunn","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ijtb.2018.07.004_bib51","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2217\/fmb.11.46","article-title":"Tuberculosis drugs: new candidates and how to find more","volume":"6","author":"Sala","year":"2011","journal-title":"Future Microbiol"},{"issue":"9731","key":"10.1016\/j.ijtb.2018.07.004_bib52","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(10)60359-9","article-title":"Global tuberculosis drug development pipeline: the need and the reality","volume":"375","author":"Ma","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijtb.2018.07.004_bib53","article-title":"Tackling drug-resistant tuberculosis: current trends and approaches","author":"Tandon","year":"2016","journal-title":"Mini Rev Med Chem"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570717303700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570717303700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:57:33Z","timestamp":1758081453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570717303700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0019570717303700"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2018.07.004","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of new drug-regimens against multidrug-resistant tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2018.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V. on behalf of Tuberculosis Association of India.","name":"copyright","label":"Copyright"}]}}